- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02282982
Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis (SUNRISE)
29 juni 2016 uppdaterad av: AbbVie
Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis in Routine Clinical Setting in the Russian Federation
This was a non-interventional, prospective, multi-center study with no control group designed to assess the effectiveness of palivizumab in a population of infants at high-risk of serious Respiratory Syncytial Virus (RSV) illness (infants born ≤ 35 weeks of gestation and infants ≤24 months with Bronchopulmonary Dysplasia (BPD) or Congenital Heart Disease (CHD)).
Participants received immunoprophylaxis during the RSV season, defined as October 2014 through April 2015, in routine clinical settings throughout the Russian Federation.
Studieöversikt
Status
Avslutad
Betingelser
Detaljerad beskrivning
Participants received intramuscular injections of palivizumab according to physicians' prescription and the local label.
The local label recommended 1 month injection intervals between 5 sequential injections at a dose of 15 mg/kg.
Participants could have received from 3 to 5 monthly injections of palivizumab during the 2014 - 2015 RSV season and the duration of this study.
Studietyp
Observationell
Inskrivning (Faktisk)
359
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
Inte äldre än 7 månader (Barn)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Testmetod
Icke-sannolikhetsprov
Studera befolkning
Infants at high-risk of serious Respiratory Syncytial Virus (RSV) illness (infants born ≤ 35 weeks of gestation and infants ≤24 months with Bronchopulmonary Dysplasia (BPD) or Congenital Heart Disease (CHD)) who received immunoprophylaxis during the RSV season defined as October 2014 through April 2015 in routine clinical settings in the Russian Federation.
Beskrivning
Inclusion Criteria:
- Planned prescription of palivizumab for immunoprophylaxis during RSV season or participants for whom palivizumab was prescribed and who received the first dose of palivizumab no later than 60 days before enrollment in the study
Infants at high risk of severe RSV infection defined as fulfilling at least one of the following:
- Infants born ≤35 weeks gestational age AND are ≤6 months of age at the onset of the RSV season;
- Infants ≤24 months of age AND with a diagnosis of BPD (defined as oxygen requirement at a corrected gestational age of 36 weeks);
- Infants ≤24 months of age with hemodynamically significant CHD, unoperated or partially corrected.
- Written authorization to use individual data signed by parents or child representative
Exclusion Criteria:
- Major congenital malformation aside from CHD
- Chronic pulmonary disease other than BPD
- Acute period of any infection
- Contraindication to palivizumab prescription according to local label
- Administration of a product possibly containing RSV-neutralizing antibody within 30 days prior to enrollment or current administration (includes, but is not restricted to, the following: RSV hyperimmunoglobulin, polyclonal intravenous immunoglobulin, cytomegalovirus hyperimmunoglobulin, varicella zoster hyperimmunoglobulin)
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Kohort
- Tidsperspektiv: Blivande
Kohorter och interventioner
Grupp / Kohort |
---|
Infants at high-risk of serious RSV illness
Infants who received immunoprophylaxis during the RSV season
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Proportion of Infants Hospitalized for Lower Respiratory Tract Infection (LRTI) With a Positive Respiratory Syncytial Virus (RSV) Diagnostic Test
Tidsram: Approximately 7 months
|
Hospitalizations for LRTI with positive RSV diagnostic tests were documented at study visits.
|
Approximately 7 months
|
Proportion of Infants Who Died From a Confirmed Respiratory Syncytial Virus (RSV) Infection
Tidsram: Approximately 7 months
|
Deaths caused by RSV during the study were to be confirmed by autopsy or clinical history and positive virologic diagnostic tests.
|
Approximately 7 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Median Length of Stay (LOS) of Lower Respiratory Tract Infection (LRTI) Hospitalization With a Positive Respiratory Syncytial Virus (RSV) Test
Tidsram: Approximately 7 months
|
The duration of hospitalizations due to LRTI which were accompanied by a positive RSV diagnostic test was documented.
|
Approximately 7 months
|
Proportion of Participants With Intensive Care Unit (ICU) Admission Among Hospitalized Participants
Tidsram: Approximately 7 months
|
The number of hospitalized participants admitted to the Intensive Care Unit was documented.
|
Approximately 7 months
|
Median Length of Stay (LOS) of Participants in the Intensive Care Unit (ICU)
Tidsram: Approximately 7 months
|
The median length of stay of hospitalized participants in the Intensive Care Unit was calculated.
|
Approximately 7 months
|
Proportion of Participants Who Received Supplemental Oxygen While Hospitalized
Tidsram: Approximately 7 months
|
The proportion of participants who received supplemental oxygen while hospitalized was documented.
|
Approximately 7 months
|
Proportion of Participants Who Received Mechanical Ventilation While Hospitalized
Tidsram: Approximately 7 months
|
The proportion of participants who received mechanical ventilation while hospitalized was documented.
|
Approximately 7 months
|
Proportion of Participants With Missed Doses of Palivizumab
Tidsram: Approximately 7 months
|
The proportion of participants with missed or delayed doses of palivizumab was documented.
|
Approximately 7 months
|
Proportion of Participants With Co-morbidities During Hospitalizations
Tidsram: Approximately 7 months
|
The proportion of participants with co-morbidities during hospitalizations was documented.
Co-morbidities were defined by the International Statistical Classification of Diseases 10 revision (ICD-10).
|
Approximately 7 months
|
Median Duration of Mechanical Ventilation Administration During Hospitalizations
Tidsram: Approximately 7 months
|
The median duration of mechanical ventilation administration during hospitalizations was calculated.
|
Approximately 7 months
|
Median Duration of Oxygen Administration During Hospitalizations
Tidsram: Approximately 7 months
|
The median duration of mechanical oxygen administration during hospitalizations was calculated.
|
Approximately 7 months
|
Proportion of Participants With a Particular Co-morbidity
Tidsram: Approximately 7 months
|
The proportion of participants with co-morbidities was documented.
Co-morbidities were defined by the International Statistical Classification of Diseases 10 revision (ICD-10).
|
Approximately 7 months
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Studierektor: Andrey Strugovschikov, MD, AbbVie
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Användbara länkar
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 oktober 2014
Primärt slutförande (Faktisk)
1 maj 2015
Avslutad studie (Faktisk)
1 maj 2015
Studieregistreringsdatum
Först inskickad
3 november 2014
Först inskickad som uppfyllde QC-kriterierna
3 november 2014
Första postat (Uppskatta)
5 november 2014
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
29 juli 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
29 juni 2016
Senast verifierad
1 juni 2016
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- P14-579
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Respiratory Syncytial Virus (RSV)
-
Enanta Pharmaceuticals, IncRekryteringRespiratory Syncytial Virus (RSV)Förenta staterna, Spanien, Israel, Australien, Tyskland, Korea, Republiken av, Taiwan, Storbritannien, Argentina, Brasilien, Nya Zeeland, Polen, Rumänien, Sydafrika, Mexiko
-
NovavaxAvslutadRespiratory Syncytial Virus (RSV)Förenta staterna
-
NovavaxAvslutadRespiratory Syncytial Virus (RSV)Förenta staterna
-
VaxartAvslutadRespiratory Syncytial Virus (RSV)Förenta staterna
-
NovavaxAvslutadRespiratory Syncytial Virus (RSV)Förenta staterna
-
MedImmune LLCAvslutadRespiratory Syncytial Virus (RSV)Förenta staterna
-
University of RochesterAktiv, inte rekryterandeRespiratory Syncytial Virus (RSV)Förenta staterna
-
University of OxfordInnovative Medicines Initiative; Respiratory syncytial virus consortium...Aktiv, inte rekryterandeRespiratory Syncytial Virus (RSV)Storbritannien
-
Enanta Pharmaceuticals, IncAvslutadRespiratory Syncytial Virus (RSV)Förenta staterna
-
GlaxoSmithKlineAvslutadRespiratory Syncytial Virus (RSV)Belgien